Comparison of HPV genotyping assays and hybrid capture 2 for detection of high-risk HPV in cervical specimens

Annals of Clinical and Laboratory Science

Volumn 41, Issue 1, 2011, Pages 48-55

  Um, Tae Hyun ^a   Lee, Eun Hee ^b   Chi, Hyun Sook ^c   Kim, Jong Won ^d   Hong, Young Joon ^e   Cha, Young Joo ^f  

^a Inje University   (South Korea)

^b Green Cross Reference Laboratory   (South Korea)

^c University of Ulsan   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Korea Cancer Center Hospital   (South Korea)

^f Chung Ang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; FEMALE; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; NONHUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

BIOLOGICAL ASSAY; CERVIX UTERI; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; REAGENT KITS, DIAGNOSTIC; RISK FACTORS; VAGINAL SMEARS;

HUMAN PAPILLOMAVIRUS;

EID: 79951922156     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Munõz N, Bosch FX, Sanjosé Sd, Herrero R, Castellsagué X, Shah KV, Snijders PJF, Meijer CJLM. Epidemiologic classification of human papillomavirus types associated with cervical cancer. NEJM 2003;348:518-527. (Pubitemid 36159887)
2. Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, ter Harmsel B, Quint W. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papilloma-viruses. Am J Pathol 1998;153: 1731-1739. (Pubitemid 28550661)
3. Elfgren K, Jacobs M, Walboomers JM, Meijer CJ, Dillner J. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynec 2002;100:965-971. (Pubitemid 35387469)
4. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, Coutlee F, Franco EL. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomark Prev 2003;12: 485-490. (Pubitemid 36713640)
5. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002;325:572.
6. Wallin K-L, Wiklund F, Ångström T, Bergman F, Stendahl U, Wadell G, Hallmans G, Dillner J. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. NEJM 1999;341:1633-1638.
7. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis. Br J Cancer 2003; 88:63-73.
8. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiff-man M. The elevated 10-year risk of cervical precancer and cancer in women with human papilloma-virus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. JNCI 2005;97: 1072-1079. (Pubitemid 41417924)
9. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76-84. (Pubitemid 40725441)
10. Schiffman M, Wheeler CM, Dasgupta A, Solomon D, Castle PE. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Papanicolaou smears. Am J Clin Pathol 2005;124:722-732. (Pubitemid 41532507)
11. Cuschieri KS, Cubie HA. The role of human papillomavirus testing in cervical screening. J Clin Virol 2005;32:S34-42.
12. Masumoto N, Fujii T, Ishikawa M, Mukai M, Saito M, Iwata T, Fukuchi T, Kubushiro K, Tsukazaki K, Nozawa S. Papanicolaou tests and molecular analyses using new fluid-based specimen collection technology in 3000 Japanese women. Br J Cancer 2003;88:1883-1888. (Pubitemid 36829663)
13. Sarode VR, Werner C, Gander R, Foster B, Fulmer A, Saboorian MH, Ashfaq R. Reflex human papillomavirus DNA testing on residual liquid-based (TPPT) cervical samples: focus on age-stratified clinical performance. Cancer 2003;99:149-155. (Pubitemid 36713634)
14. Poljak M, Brencic A, Seme K, Vince A, Marin IJ. Comparative evaluation of first- and second-generation digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer. J Clin Microbiol 1999;37:796-797. (Pubitemid 29091309)
15. Castle PE, Wheeler CM, Solomon D, Schiffman M, Peyton CL. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol 2004; 122:238-245. (Pubitemid 38971357)
16. Kulmala SM, Syrjanen S, Shabalova I, Petrovichev N, Kozachenko V, Podistov J, Ivanchenko O, Zakharenko S, Nerovjna R, Kljukina L, Branovskaja M, Grunberga V, Juschenko A, Tosi P, Santopietro R, Syrjanen K. Human papillo-mavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol 2004;42:2470-2475. (Pubitemid 38747492)
17. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354:20-25. (Pubitemid 29304297)
18. An HJ, Cho NH, Lee SY, Kim IH, Lee C, Kim SJ, Mun MS, Kim SH, Jeong JK. Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. Cancer 2003;97:1672-1680.
19. Hwang HS, Park M, Lee SY, Kwon KH, Pang MG. Distribution and prevalence of human papillo-mavirus genotypes in routine pap smear of 2,470 korean women determined by DNA chip. Cancer Epidemiol Biomark Prev 2004;13: 2153-2156. (Pubitemid 40054311)
20. Lee EH, Chung HJ, Oh HB, Chi HS, Jee MS, Park SN, Hong SP, Yoo W, Kim SO. Human papilloma virus genotyping assay using restriction fragment mass polymorphism analysis, and its comparison with sequencing and hybrid capture assays. Korean J Lab Med 2007;27:62-68.
21. Lee GY, Kim SM, Rim SY, Choi HS, Park CS, Nam JH. Human papillomavirus (HPV) genotyping by HPV DNA chip in cervical cancer and precancerous lesions. Int J Gynecol Cancer 2005;15:81-87.
22. Choi YD, Jung WW, Nam JH, Choi HS, Park CS. Detection of HPV genotypes in cervical lesions by the HPV DNA chip and sequencing. Gynecol Oncology 2005;98:369-375.
23. Lee JK, Kim MK, Song SH, Hong JH, Min KJ, Kim JH, Song ES, Lee J, Lee JM, Hur SY. Comparison of human papillomavirus detection and typing by hybrid capture 2, linear array, DNA chip, and cycle sequencing in cervical swab samples. Int J Gynecol Cancer 2009;19:266-272.
24. Davies P, Kornegay J, Iftner T. Current methods of testing for human papillomavirus. Best Pract Res Clin Obstet Gynaecol 2001; 15:677-700. (Pubitemid 33026194)
25. Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: Baseline data from a randomized trial. JNCI 2000;92:397-402.
26. Snijders PJ, Van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003;201:1-6. (Pubitemid 37121197)
27. Poljak M, Marin IJ, Seme K, Vince A. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol 2002;25:S89-97.